Pharmafile Logo

Cuttsy+Cuttsy awarded CPD Platinum by the IPA

Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation.

- PMLiVE

Platinum is only awarded to agencies who have reached gold level four years out of five and C+C have done it in their first four years of full membership of the IPA. In 2018 the agency team completed 905 hours of professional development vs. the 333 hours that agency needed to meet the IPA standard requirements.

On receiving the news Mathew Cutts, Co-Founder and Director spoke about the importance of the award ‘The workplace is evolving very quickly and attracting and retaining great people is no longer just about salary and a bonus. People are looking for many different aspects of employment, such as flexible working, having a career that makes a difference, progression and of course the chance to learn. This award is testament to the team and their thirst to want to continually improve it also evidences our commitment to the growth of individuals as well as the company’.

Kate McCabe, HR manager who is responsible for the initiative talked about what it takes to become a Platinum award winner. ‘Hard work and dedication, but more importantly, a commitment to truly investing in the belief that developing your team will not only develop and grow the business but motivate and retain the best people. Ultimately, providing a first-class service to your clients and for us most importantly, patients.

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

Invited, but not equipped: patient involvement needs more than an open door

Explore how pharma can help patients and patient organisations prepare for meaningful involvement in EU HTA without shaping their contribution.

The outcomes are already chosen. So when can patients really shape them?

Explore why involving patients early in Joint Scientific Consultations is critical to shaping the outcomes measured in clinical trials.

Long-term clinical trial engagement is a behavioural challenge – not just an informational one

Explore why long-term clinical trial engagement is a behavioural challenge, showing how proactive support from site teams can help participants stay connected, confident and committed throughout a study.

Patients are telling the truth — just not to you

Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.

When what matters to patients is hard to measure

Patient-relevant outcomes sit at the heart of the EU HTA reforms, but ensuring they reflect lived experience requires you to look beyond what traditional clinical endpoints measure.

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

A seat at the table: what the EU HTA reforms really ask of patient involvement

The EU HTA reforms give patients a formal role in assessing new medicines, but meaningful involvement requires more than simply offering them a seat at the table.

Why faster trials make participant understanding more important than ever

As clinical trials accelerate, clear, accessible consent is essential to help participants understand, engage with and remain in a study.

Older trial participants reject bad design, not technology

Older trial participants aren’t rejecting digital technology — they’re rejecting poorly designed, inaccessible experiences that make participation harder.

5 key takeaways from the Patient Centricity and Engagement Conference

Key takeaways from the Patient Centricity and Engagement conference, exploring how trust, inclusion and meaningful partnership can help turn patient engagement from intention into action.